Evidence map›Paper›PMID 34671121›Full record

ArticleBone marrow transplantation2022

Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.

M L Dworkin, A L Jiang, R Von Eyben, M A Spinner, R H Advani, R Lowsky, S M Hiniker, R T Hoppe

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

M L DworkinDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
A L JiangDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
R Von EybenDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
M A SpinnerDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
R H AdvaniDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
R LowskyDepartment of Medicine, Division of Blood and Marrow Transplantation, Stanford Cancer Institute, Stanford, CA, USA.
S M Hiniker *Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
R T Hoppe *Department of Radiation Oncology, Stanford University, Stanford, CA, USA. rhoppe@stanford.edu.
Stanford University · USStanford Blood Center · USStanford Medicine · US

Funding

TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
NCI NIH HHS P01 CA049605
6 · The paper itself

Abstract

We evaluated the impact on survival of antithymocyte globulin conditioning (TLI-ATG) with radiation (RT) boost to high risk or residual disease before allogeneic hematopoietic cell transplant (allo-HCT) for adults with lymphoma (excluding mycosis fungoides and low-grade NHL other than SLL/CLL). Of 251 evaluable patients, 36 received an RT boost within 3 months of allo-HCT at our institution from 2001 to 2016. At the time of TLI-ATG, patients who received boost vs no boost had a lower rate of CR (11% vs 47%, p = 0.0003), higher rates of bulky disease (22% vs 4%, p < 0.0001), extranodal disease (39% vs 5%, p < 0.0001), and positive PET (75% vs 28%, p < 0.00001). In the boost group, the median (range) largest axial lesion diameter was 5.2 cm (1.8-22.3). Median follow-up was 50.2 months (range: 1-196). There was no significant difference in OS, time to recurrence, or time to graft failure with vs without boost. A trend toward higher percent donor CD3

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLymphomaAdultAntilymphocyte SerumHumansNeoplasm, ResidualTransplantation ConditioningTransplantation, HomologousAntilymphocyte Serum

Identifiers

PMID34671121
OpenAlexW3206963392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.